上方“瞪羚社”即刻关注并加入社群聚焦高成长公司,100000+投资菁英共同关注加科思前几天的BD惊艳了整个医药界,pan-Kras抑制剂也因此而一战成名。那么,随着MNC正在争相布局这个靶点的时刻,中国是否还有别的相关标的值得关注?当然有,劲方医药的管线和加科思拥有非常多的相似性,管线结构质地很不错,其惊艳的管线Kras G12C和Kras G12D抑制剂我们已经在之前有过叙述,并且,它的...
Source Link上方“瞪羚社”即刻关注并加入社群聚焦高成长公司,100000+投资菁英共同关注加科思前几天的BD惊艳了整个医药界,pan-Kras抑制剂也因此而一战成名。那么,随着MNC正在争相布局这个靶点的时刻,中国是否还有别的相关标的值得关注?当然有,劲方医药的管线和加科思拥有非常多的相似性,管线结构质地很不错,其惊艳的管线Kras G12C和Kras G12D抑制剂我们已经在之前有过叙述,并且,它的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.